Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anita Milicic


Group Leader, Vaccine Formulation and Adjuvants

  • Head of VFI-Oxford Adjuvant Programme
  • Jenner Institute Lead for Public Engagement

I studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford.

In 2009 I joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility. I now lead the Vaccine Formulation and Adjuvants Group, developing novel vaccine formulations and delivery modalities. Specifically, our work is focused on the development of new adjuvants with a key emphasis on understanding the adjuvant mechanism of action with the goal of improved vaccine efficacy.

My overall interest is in the processes of immune activation, in particular the interplay between the innate and the adaptive immunity. Vaccine development with the application of vaccine adjuvants provides the ideal base for such studies.

Apart from research, I am involved in teaching within the University and externally (Milicic, A., Vaccination [Video file], Henry Stewart Talks: The Biomedical & Life Sciences Collection, 2021) and writing popular science articles on vaccination and vaccine adjuvants.

I am a Core Group member and Working Group leader in the EU COST Action Programme ENOVA (European Network of Vaccine Adjuvants). I am also the Jenner Institute lead for Public Engagement with Research.

Recent publications

More publications